Presentation on theme: "Case no. 7. Eva Honsova Institute for Clinical and Experimental Medicine Pathology Department Prague, Czech Republic"— Presentation transcript:
Case no. 7. Eva Honsova Institute for Clinical and Experimental Medicine Pathology Department Prague, Czech Republic firstname.lastname@example.org
Clinical history A 55 y/o woman was admitted to our transplant centre to be considered for the second renal transplant She had agenesis of the left kidney and several stenotic segments in the right ureter: repeated pyelonephritides Partial resection of the right kidney: when she was 15 year old Haemodialysis started when she was 35 y/o. A year later she received a cadaveric kidney and that graft functioned for 18 years.
Clinical history Graftectomia. After one year on dialysis she received the 2nd cadaveric kidney transplant (AB0 compatible) The donor: 61y/o woman who died of cerebral edema due to pulmonary embolism. No induction therapy (0% PRA) and the recipient received standard triple IS protocol therapy (prednisone, tacrolimus, MMF). Delayed graft function, and a renal biopsy was performed on POD6.
Biopsy sample: 6 th day C4d staining negative (IF) Dg.: Acute T cell rejection, grade IIA, acute tubular injury
Clinical course Treatment: solumedrol. Her renal function slowly improved and the S-Cr stabilized on 170μmol/l (1.9mg/dl). She developed pollen allergy with asthmatic problems High level of Tacrolimus was identified (tac 17.2 ng/ml), 8ng/ml She felt well and came to the our centre 3 months later for a graft biopsy according to the protocol (S-Cr was between 130-160μmol/l)
2nd biopsy sample (under protocol, 3 months) C4d staining negative (IF) Dg.: Acute T-cell-mediated rejection, grade IIB, interstitial inflammation as a part of rejection, glomerulitis No TMA, mild arteriolar lesions
Clinical course She was treated with thymoglobulin and S-Cr improved and descended on the level of 110μmol/l. She remained well but her renal dysfunction slowly progressed A new graft biopsy for graft dysfunction (S-Cr 160- 200μmol/l) was performed 2 years later.
3rd biopsy sample (for dysfunction, 2 years post transplant) C4d staining negative (IF and IH) Dg.: Morphological features of C4d negative humoral rejection Repeated cross match and Luminex were negative.
Clinical course Progressive anemia with reticulocytopenia Infection by parvovirus B19 was diagnosed (consistent sternal bone marrow smear, virus DNA and IgM antibodies in serum). Therapy: ivIgs, IS continued 2 years later: a liver mass (4cm) which was considered FNH. Normal architecture of the liver tissue.
4th biopsy sample (for dysfunction, 5 years postTx, S-Cr 300μmol/l; 3.39mg/dl; PU 4g/day) C4d staining negative (IF and IH)
4th biopsy sample ( for dysfunction, 5 years postTx, S-Cr 300μmol/l; 3.39mg/dl; PU 4g/day ) Repeated cross match and luminex were negative Ptc, BM multilayering
Summary 4 graft biopsies (all C4d negative): 1.V1, acute tubular injury 2.V2, interstitial inflammation, glomerulitis 3.Transplant glomerulopathy 4.Transplant glomerulopathy, multilayering of ptc-BM, IF/TA Clinical course: delayed function, slowly progressive dysfunction with proteinuria Pretransplant cross match negative, 0% PRA Last 2 biopsies with negative cross match, negative detection of anti HLA antibodies (luminex), negative MICA.
Acute/active antibody-mediated rejection Triad of tx glomerulopathy, C4d+, anti-DSA: dg. criteria of chronic active or persistent AMR. Both could be present at variable time points. Abs and C4d are not stable, can increase and vanish. At any given time, these factors may or may not be demonstrable, even if AMR is present. AHR has occurred with all IS regiments. The pathology of AHR has a wide spectrum of findings. However, none of these features is specific.
The problem is that when morphological features (as tx glomerulopathy) once set-in, there is not any further known treatment option to reverse CR. Only early dg. of AMR can be beneficial. Transplant glomerulopathy (cg)
Acute vascular rejection (v1, v2) and DSA Analysis of 2079 recipients with 302 biopsy proven rejections. They tested all the patients for DSA in the stored sera. 71% of cases with vascular rejection (v1, v2) were associated with DSA. More importantly, 45% v1 or v2 with DSA were C4d negative and classified as T-cell mediated rejection Lancet; 2013(381):313-319.
Luminex anti HLA anti MICA HLA class IHLA class II 1. Biopsy (IIA, v1)+ (B60)00 2. Biopsy (IIB, v2)n/d no serumn/d 3. Biopsy cg000 4. Biopsy cg, IF/TA000 HLA antigens patients1. Donor (1989)HLA incompability 2.Donor (2008)HLA incompability A3, A24A2 A31, A33 B13, B61B13, B51B51B7, B40 (B60,61)B7, B60 DR7, DR11DR7noDR4,DR7DR4
N. Angaswamy et al. / Human Immunology xxx (2013) xxx–xxx We do not know whether only low level of anti DSA (HLA class I) were the antibodies which really cause graft injury in this case. Recent evidence has demonstrated an important role of Th17 response against self-Ags as a mechanism leading to CR Perclan, collagen IV and VI, agrin The key point is inflammation Exposure of cryptic self Ags or their determinants can lead to activation of both: cell- and Abs- mediated immune responses. ??? Continuous detection of Abs
Conclusion AMR may occur in the absence of peritubular capillary C4d staining and may be difficult to identify. Correlation with DSA is helpful. However, both C4d staining and DSAb titers are not stable and can increase and vanish. Therefore at any given time these factors may and may not be demonstrable, even if AMR is or has been present. All v1 and v2 lesions may be indicative for AMR and CMR In this case, different management focused on the treatment of AMR early after Tx would have been beneficial.
Pathology - A gate to the future Future pre-congress meeting of ESP Nephropathology Working Group???